The US Court of Appeals for the Third Circuit applies an appropriate post-Actavis pleading standard (Lipitor)

On August 21, 2017, the Third Circuit overturned a decision that had applied excessive pleading standards against plaintiffs challenging reverse-payment settlements. Writing for a unanimous panel, Chief Judge Smith held that, in the wake of FTC v. Actavis, 133 S. Ct. 2223 (2013), courts should not impose reliability- or probability-based standards higher than those articulated in foundational pleading cases. The opinion consolidates cases challenging conduct related to Lipitor and Effexor XR. Factual background: Lipitor The blockbuster Lipitor drug is “designed to reduce the level of LDL cholesterol in the bloodstream.” In re Lipitor Antitrust Litig., 868 F.3d 231, 242 (3d Cir. 2017). Pfizer obtained patent protection (the “’893 patent”) on the active ingredient in 1987, expiring (after

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Michael A. Carrier, The US Court of Appeals for the Third Circuit applies an appropriate post-Actavis pleading standard (Lipitor), 21 août 2017, e-Competitions August 2017, Art. N° 84937

Visites 320

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues